advertisement
Abstract #11906 Published in IGR 7-1
Dorzolamide influences the autoregulation of major retinal vessels caused by artificial intraocular pressure elevation in patients with POAG: A clinical study
Nagel E; Vilser W; Lanzl ICurrent Eye Research 2005; 30: 129-137
PURPOSE: The study investigated whether dorzolamide influences the autoregulatory behavior of major retinal arterioles in glaucoma patients via a moderate perfusion pressure reduction. METHODS: The study included one eye each of 12 untreated patients with a primary open-angle glaucoma (POAG) (age 60.8 ± 8.3, IOP 22.3 ± 6.5 mmHg). Changes in the diameter of a retinal artery segment before (120 s), during (100 s), and after (380 s) artificial IOP elevation to 38 mmHg for 100 s were recorded continuously by means of a Retinal Vessel Analyzer. The measurement was repeated after 4-week treatment with dorzolamide eye drops t.i.d. RESULTS: Ocular perfusion pressure (mmHg) was reduced by the intraocular pressure (IOP) elevation from 58 (± 10) to 41 (± 11) in the pretreatment examination and from 60 (± 8) to 40 (± 8) posttreatment (differences between the examinations n.s.). Before IOP elevation, the arterial diameter was found to be +1.7 ± 3.5% greater in the posttreated eyes than in the pretreated eyes (p < 0.02). During IOP elevation, the arterial diameter decreased by -1.8% ± 3.8 in the pretreated eyes, whereas dilatation by +1.4% ± 2.5 was observed in the posttreated eyes (p = 0.02). At the end of the observation period following IOP elevation, the vessel diameter in the pretreated eyes had increased by +1.8% ± 4.2, whereas in the posttreated eyes it had decreased by -1.7% ± 3.0. On average, dorzolamide reduced IOP by -5.6 mmHg (p = 0.001). CONCLUSIONS: The arterial diameter dilatation during IOP elevation in dorzolamide-treated eyes could be an accelerated counter-regulation on the induced elevated IOP and could constitute an additional therapeutic effect.
Dr. E. Nagel, Rudolstadt Ophthalmologic Practice, Rudolstadt, Germany. e_a_nagel@t-online.de
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)